Allogene Takes Step Closer To Off-The-Shelf CAR-Ts

 
• By Mary Jo Laffler

Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion. 

Road_Arrows
Allogene Is on track to take ALLO-501A into Phase II

More from ASCO

More from Conferences